Market Cap
$27.7M
KPTI
Karyopharm Therapeutics Inc.
$0.8050 ▼ -7.15%
Prev close $0.8670Market cap$27.7M
ConsensusStrong Buy
12-mo target$7.25 (+800.6%)
▲ Bullish
Analyst conviction 8/10
Insider Selling Cluster (6 insiders)High Impact Filing (9/10)20 New Institutional Positions4 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on KPTI right now — valuation, ownership and activity at a glance.
Cap Size
Nano Cap
Analyst Consensus
Strong Buy (82%)
Inst. Holders
50 funds
Inst. Value
$130.9M
Inst. Activity
20 buys / 4 sells
Insider Activity
$0.00 buy / $296.1K sell
Insider Net $
-$296.1K
Social Sentiment
50° Neutral
SEC Reports
17
Price chart 30d -55.0%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 other
Sep 11, 2026 SEC Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Oct. 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercia
Karyopharm Therapeutics has entered into a forbearance agreement with 100% of its term loan lenders, convertible notehol
8-K — Impact 9/10
Sep 1, 2026 Insider
Aug 31, 2026 SEC Abate Kristin sold 19 shares
Chief Accounting Officer @ $2.02 ($38.38)
Karyopharm announced submission of an sNDA to the FDA seeking Accelerated Approval for XPOVIO (selinexor) in combination
8-K — Impact 6/10
Karyopharm reported Q2 2026 total revenue of $33.4M, down 12% YoY from $37.9M, driven by a $5.6M decline in license and
8-K — Impact 8/10
Jul 28, 2026 Insider
Poulton Stuart sold 189 shares
EVP, Chief Development Officer @ $7.10 ($1.3K)
Jun 30, 2026 Inst.
GOLDMAN SACHS GROUP INC — ADD
1,424,658 shares ($13.9M)
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
1,418,799 shares ($13.9M)
Analyst ratings buy % -1.2%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
82% rate it Buy or better · 11 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Jul 31, 2026 | Piper Sandler | MAINTAIN | Overweight | 54% |
| Jul 31, 2026 | HC Wainwright & Co. | DOWNGRADE | Neutral | 43% |
| May 6, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Apr 27, 2026 | Piper Sandler | REITERATE | Overweight | 54% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 3 | 6 | 2 | 0 | 0 | 82% | |
| Aug 1, 2026 | 3 | 6 | 3 | 0 | 0 | 75% | |
| Jul 1, 2026 | 4 | 7 | 2 | 0 | 0 | 85% | |
| Jun 1, 2026 | 4 | 7 | 2 | 0 | 0 | 85% | |
| May 1, 2026 | 4 | 7 | 2 | 0 | 0 | 85% | |
| Apr 1, 2026 | 4 | 7 | 2 | 0 | 0 | 85% | |
| Mar 1, 2026 | 4 | 7 | 2 | 0 | 0 | 85% | |
| Feb 1, 2026 | 4 | 6 | 2 | 0 | 0 | 83% |
Price targets
Where 4 covering analysts think KPTI trades over the next 12 months.
$7.25 +800.6% upside Strong Buy
Current$0.8050 Low$3.00 Median$7.50 High$11.00 4 analysts
$3.00$11.00
Analyst rating None as of Oct 2, 2026
Social media sentiment
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
17 SEC filing reports analyzed · 1 bullish, 7 bearish, 2 mixed, 7 neutral · avg impact 5.2/10.
BEARISH8-K9/10
Karyopharm Therapeutics has entered into a forbearance agreement with 100% of its term loan lenders,
Sep 11, 2026
BULLISH8-K6/10
Karyopharm announced submission of an sNDA to the FDA seeking Accelerated Approval for XPOVIO (selin
Aug 31, 2026
BEARISH8-K8/10
Karyopharm reported Q2 2026 total revenue of $33.4M, down 12% YoY from $37.9M, driven by a $5.6M dec
Aug 13, 2026
NEUTRALPRESS-RELEASE2/10
Karyopharm Therapeutics announced it will report Q2 2026 financial results on August 13, 2026. This
Aug 10, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
other
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Oct. 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel ca
Sep 29, 2026
short_volume
Short Volume: KPTI — 66.8% short (0.7M / 1.1M)
Short: 727,885 | Exempt: 86,725 | TRF Vol: 1,090,138 | Short Ratio: 66.8% | Off-exchange volume (dark pool + OTC)
Sep 16, 2026
Clinical Trial
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Phase Phase 3 — ACTIVE_NOT_RECRUITING
Sep 16, 2026
Clinical Trial
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Phase Phase 2 — ACTIVE_NOT_RECRUITING
Sep 16, 2026
clinical_trial_readout
T-90d Trial Readout: Selinexor (Phase 2)
Trial: Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Sponsor: Karyopharm Therapeutics Inc Phase: Phas
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-1.31 | $-1.37–$-1.26 | 65.6% | -8.4% | 1↑ 1↓ | $0.0B | 2 |
| Next Q | $-1.21 | $-1.30–$-1.12 | 45.7% | +1.6% | 1↑ 1↓ | $0.0B | 2 |
| Current FY | $-5.84 | $-6.01–$-5.68 | 52.2% | -18.0% | 1↑ 1↓ | $0.1B | 2 |
| Next FY | $-2.82 | $-3.72–$-1.92 | 51.7% | +42.3% | 2↑ 0↓ | $0.2B | 2 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-1.315 | — |
| 7d ago | $-1.457 | +0.142 |
| 30d ago | $-1.213 | -0.102 |
| 60d ago | $-1.213 | -0.102 |
| 90d ago | $-1.213 | -0.102 |
Institutional ownership
Which big funds own KPTI (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $130.9M total value (13,391,839 shares) as of 2026-Q2. Top holders: RA, ADAGE, GOLDMAN. Net buying activity: 20 institutions added/increased vs 4 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 1,917,354 | $18.7M | 14.3% | NEW |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,521,322 | $14.9M | 11.4% | DOUBLED +328.7% |
| GOLDMAN SACHS GROUP INC | 1,424,658 | $13.9M | 10.6% | ADD +50.3% |
| BlackRock, Inc. | 1,418,799 | $13.9M | 10.6% | DOUBLED +479.3% |
| VANGUARD CAPITAL MANAGEMENT LLC | 958,979 | $9.4M | 7.2% | ADD +29.6% |
| TWO SIGMA INVESTMENTS, LP | 695,264 | $6.8M | 5.2% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 531,231 | $5.2M | 4.0% | DOUBLED +157.7% |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 484,800 | $4.7M | 3.6% | — |
| UBS Group AG | 353,545 | $3.5M | 2.6% | ADD +82.2% |
| STATE STREET CORP | 325,991 | $3.2M | 2.4% | DOUBLED +303.7% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| GOLDMAN SACHS GROUP INC | ADD | 947,579 | 1,424,658 | +50.3% | $13.9M |
| BlackRock, Inc. | DOUBLED | 244,899 | 1,418,799 | +479.3% | $13.9M |
| VANGUARD CAPITAL MANAGEMENT LLC | ADD | 739,745 | 958,979 | +29.6% | $9.4M |
| GEODE CAPITAL MANAGEMENT, LLC | DOUBLED | 206,133 | 531,231 | +157.7% | $5.2M |
| UBS Group AG | ADD | 194,017 | 353,545 | +82.2% | $3.5M |
| STATE STREET CORP | DOUBLED | 80,742 | 325,991 | +303.7% | $3.2M |
| Brevan Howard Capital Management LP | ADD | 212,367 | 309,817 | +45.9% | $3.0M |
| MILLENNIUM MANAGEMENT LLC | TRIM | 420,571 | 305,676 | -27.3% | $3.0M |
| JPMORGAN CHASE & CO | DOUBLED | 471 | 207,609 | +43978.3% | $2.1M |
| MORGAN STANLEY | DOUBLED | 18,570 | 202,506 | +990.5% | $2.0M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
11 insiders, 31 transactions. Net -$296.1K — $0.00 bought, $296.1K sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | Abate Kristin | Chief Accounting Officer | SELL | 19 | $2.02 | $38.38 |
| Jul 28, 2026 | Poulton Stuart | EVP, Chief Development Officer | SELL | 189 | $7.10 | $1.3K |
| May 21, 2026 | Greene Barry E | Director | AWARD | 15,508 | — | — |
| May 21, 2026 | Su Zhen | Director | AWARD | 15,508 | — | — |
| May 21, 2026 | Schor Chen | Director | AWARD | 15,508 | — | — |
| May 21, 2026 | Oliger Christy J. | Director | AWARD | 15,508 | — | — |
| May 14, 2026 | Mano Michael | EVP, CLO&Secretary | SELL | 266 | $9.50 | $2.5K |
| May 14, 2026 | Paulson Richard A. | President and CEO | SELL | 2,203 | $9.50 | $20.9K |
| May 14, 2026 | Abate Kristin | Chief Accounting Officer | SELL | 53 | $9.50 | $503.50 |
| May 14, 2026 | Cheng Sohanya Roshan | EVP & Chief Commercial Officer | SELL | 324 | $9.50 | $3.1K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for KPTI.
Shares short
7,865,168
Settlement Sep 15, 2026
Change vs prior
-19.9%
Semi-monthly cycle
Days to cover
5.0
At avg daily volume
Of shares outstanding
≈34.7%
Estimate — not % of float
| Halted | Code | Reason | Status |
|---|---|---|---|
| Jul 30, 2026 | T1 | News Pending | Not resumed |
| Jul 30, 2026 | T2 | News Released | Not resumed |
| Jul 30, 2026 | T3 | Resumption Scheduled | Resumed |
All KPTI filing & press-release reports (17)
- 8-K reportSep 11, 2026
- 8-K reportAug 31, 2026
- 8-K reportAug 13, 2026
- PRESS-RELEASE reportAug 10, 2026
- 8-K reportJul 31, 2026
- 8-K reportJul 17, 2026
- CLUSTER reportMay 26, 2026
- CLUSTER reportMay 26, 2026
- CLUSTER reportMay 15, 2026
- CLUSTER reportMay 15, 2026
- CLUSTER reportMay 15, 2026
- EFFECT reportMay 15, 2026
- 8-K reportMay 14, 2026
- S-3 reportMay 4, 2026
- S-3 reportMay 4, 2026
- CLUSTER reportMar 3, 2026
- 8-K reportMar 3, 2026